Pfizer's drug hike is consistent with broad industry trends. (Photo: A./flickr/cc)
Jan 09, 2016
Former pharma CEO Martin Shkreli, widely reviled for dramatically hiking the price of a life-saving drug used by HIV and cancer patients, is in good company.
Starting at the beginning of 2016, the pharmaceutical giant Pfizer Inc. quietly jacked up the U.S. prices of over 100 of its drugs, some by nearly a fifth.
Reutersreported the findings on Friday, citing statistics from the information services company Wolters Kluwer that were included in a research note from by UBS Securities.
"UBS said Pfizer increased prices by 20 percent for anticonvulsant Dilantin, hormone therapy Menest, angina drug Nitrostat, Tykosyn for irregular heartbeat, and antibiotic Tygacil," Reuters noted.
"The analyst report said U.S. prices were raised on a total of 105 Pfizer drugs," the outlet continued. "No price reductions were reported."
Pfizer's drug hike is consistent with broad industry trends.
According to findings released in April by the firm Truveris, U.S. "branded, specialty and generic drugs rose a combined 3.8% in the first quarter [of 2015]."
Meanwhile, public health advocates are warning that mega "free trade" deals currently under negotiation, including the mammoth Trans-Pacific Partnership (TPP), are poised to spike drug prices even more--far beyond U.S. borders.
Judit Rius Sanjuan, U.S. manager and legal policy advisor for Doctors Without Borders, cautioned in October that "TPP countries have agreed to United States government and multinational drug company demands that will raise the price of medicines for millions by unnecessarily extending monopolies and further delaying price-lowering generic competition."
Why Your Ongoing Support Is Essential
Donald Trump’s attacks on democracy, justice, and a free press are escalating — putting everything we stand for at risk. We believe a better world is possible, but we can’t get there without your support. Common Dreams stands apart. We answer only to you — our readers, activists, and changemakers — not to billionaires or corporations. Our independence allows us to cover the vital stories that others won’t, spotlighting movements for peace, equality, and human rights. Right now, our work faces unprecedented challenges. Misinformation is spreading, journalists are under attack, and financial pressures are mounting. As a reader-supported, nonprofit newsroom, your support is crucial to keep this journalism alive. Whatever you can give — $10, $25, or $100 — helps us stay strong and responsive when the world needs us most. Together, we’ll continue to build the independent, courageous journalism our movement relies on. Thank you for being part of this community. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Sarah Lazare
Sarah Lazare is web editor at In These Times. She is a former Staff Writer at Common Dreams. She comes from a background in independent journalism for publications including The Intercept, The Nation, and Tom Dispatch.
Former pharma CEO Martin Shkreli, widely reviled for dramatically hiking the price of a life-saving drug used by HIV and cancer patients, is in good company.
Starting at the beginning of 2016, the pharmaceutical giant Pfizer Inc. quietly jacked up the U.S. prices of over 100 of its drugs, some by nearly a fifth.
Reutersreported the findings on Friday, citing statistics from the information services company Wolters Kluwer that were included in a research note from by UBS Securities.
"UBS said Pfizer increased prices by 20 percent for anticonvulsant Dilantin, hormone therapy Menest, angina drug Nitrostat, Tykosyn for irregular heartbeat, and antibiotic Tygacil," Reuters noted.
"The analyst report said U.S. prices were raised on a total of 105 Pfizer drugs," the outlet continued. "No price reductions were reported."
Pfizer's drug hike is consistent with broad industry trends.
According to findings released in April by the firm Truveris, U.S. "branded, specialty and generic drugs rose a combined 3.8% in the first quarter [of 2015]."
Meanwhile, public health advocates are warning that mega "free trade" deals currently under negotiation, including the mammoth Trans-Pacific Partnership (TPP), are poised to spike drug prices even more--far beyond U.S. borders.
Judit Rius Sanjuan, U.S. manager and legal policy advisor for Doctors Without Borders, cautioned in October that "TPP countries have agreed to United States government and multinational drug company demands that will raise the price of medicines for millions by unnecessarily extending monopolies and further delaying price-lowering generic competition."
Sarah Lazare
Sarah Lazare is web editor at In These Times. She is a former Staff Writer at Common Dreams. She comes from a background in independent journalism for publications including The Intercept, The Nation, and Tom Dispatch.
Former pharma CEO Martin Shkreli, widely reviled for dramatically hiking the price of a life-saving drug used by HIV and cancer patients, is in good company.
Starting at the beginning of 2016, the pharmaceutical giant Pfizer Inc. quietly jacked up the U.S. prices of over 100 of its drugs, some by nearly a fifth.
Reutersreported the findings on Friday, citing statistics from the information services company Wolters Kluwer that were included in a research note from by UBS Securities.
"UBS said Pfizer increased prices by 20 percent for anticonvulsant Dilantin, hormone therapy Menest, angina drug Nitrostat, Tykosyn for irregular heartbeat, and antibiotic Tygacil," Reuters noted.
"The analyst report said U.S. prices were raised on a total of 105 Pfizer drugs," the outlet continued. "No price reductions were reported."
Pfizer's drug hike is consistent with broad industry trends.
According to findings released in April by the firm Truveris, U.S. "branded, specialty and generic drugs rose a combined 3.8% in the first quarter [of 2015]."
Meanwhile, public health advocates are warning that mega "free trade" deals currently under negotiation, including the mammoth Trans-Pacific Partnership (TPP), are poised to spike drug prices even more--far beyond U.S. borders.
Judit Rius Sanjuan, U.S. manager and legal policy advisor for Doctors Without Borders, cautioned in October that "TPP countries have agreed to United States government and multinational drug company demands that will raise the price of medicines for millions by unnecessarily extending monopolies and further delaying price-lowering generic competition."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.